FORT DETRICK, Md. – On August 13, 2024, the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) participated in a kick-off meeting with Phlow Corporation at its facility in Petersburg, Virginia. This meeting marked the start of work on a JPEO-CBRND-led advanced manufacturing effort for active pharmaceutical ingredients, which are used to develop medical countermeasure drug products that support the joint force and its allies in counteracting chemical and biological (CB) threats.
This effort is conducted under an interagency agreement with the U.S. Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response (ASPR), which is a larger, 10-year, $1.2 billion, Cost Plus Fixed Fee contract awarded to Phlow Corp. on May 18, 2020. The contract supports the broader Department of Defense objective of expanding the domestic industrial base to reduce the inventory risk of a single source, while also mitigating capability fielding and operational readiness risks.
“This interagency partnership between the JPEO-CBRND and HHS-ASPR is critical to the National Defense Strategy and exemplifies the ongoing commitment to enhance rapid response capabilities and increase operational readiness with a domestic source of supply—compatible with HHS requirements—to ensure effective emergency response across agencies,” said COL Matthew Clark, Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), a component of the JPEO-CBRND. “The JPEO-CBRND mission is complementary to the HHS health mission, and this partnership highlights our shared commitment in continuing to provide a layered defense against CB threats to the warfighter.”
